Need to assess the effect of therapy? Ask the patient!

Achieving a good treatment outcome in rheumatic diseases (RD) requires regular, dynamic patient monitoring and therapy correction if it is not effective or intolerant. The patient assessment must be based on clear criteria to objectify the main manifestations of the disease. For this purpose, the calculation of standard activity and severity indices (DAS28, CDAI, SDAI, BASDAI, ASDAS, DAPSA, PsARC, PASI, etc.) is used. However, this methodology does not always allow the assessment of the fundamentally important parameters of treatment outcome – patient satisfaction and well-being. According to a series of studies, poor therapy satisfaction may be observed in ≈25% of patients with systemic RD who are in remission/low disease activity according to standard indices. Moreover, in 20–30% of cases there is a major discrepancy in the assessment of therapy outcome between the patient and physician.
Therefore, a more accurate assessment of the patient’s condition requires, in addition to the calculation of standard indices, the mandatory analysis of patient-reported outcomes – pain, functional impairment, general assessment of disease activity, fatigue, etc. A valuable tool for determining well-being and good therapy outcome from the patient’s point of view is the PASS (“patient acceptable symptom state”). This simple and quite informative index correlates well with core symptoms and indicators of remission/low disease activity. PASS analysis can be used in telemedicine follow-up of patients when an objective examination is not possible. The combined use of PASS and standardized indices can better assess treatment outcomes and improve the quality of life of patients with RD.

1. Nasonov EL (ed). Rheumatology: Russian clinical recommendations Moscow:GEOTAR-Media;2020 (In Russ.).

2. Nasonov EL, Lila AM. Rheumatoid arthritis: Achievements and unresolved issues. Terapevticheskii arkhiv. 2019;91(5):4-7 (In Russ.). doi: 10.26442/00403660.2019.05.000259

3. Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: The problems of remission and therapy resistance. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(3): 363-271 (In Russ.). doi: 10.14412/1995-4484-2018-263-271

4. Gossec L, Dougados M, Dixon W. Patient-reported outcomes as end points in clinical trials in rheumatoid arthritis. RMD Open. 2015;1(1):e000019. doi: 10.1136/rmdopen-2014-000019

5. Taylor PC, Woods M, Rycroft C, Patel P, Blanthorn-Hazell S, Kent T, et al. Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom. Rheumatology (Oxford). 2021;60(11):4972-4981. doi: 10.1093/rheumatology/keab464

6. Smolen JS, Strand V, Koenig AS, Szumski A, Kotak S, Jones TV. Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res Ther. 2016;18(1):114. doi: 10.1186/s13075-016-1004-3

7. Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, et al. Determinants of patient-physician discordance in global assessment in psoriatic arthritis: A multicenter European study. Arthritis Care Res (Hoboken). 2017;69(10):1606-1611. doi: 10.1002/acr.23172

8. Desthieux C, Molto A, Granger B, Saraux A, Fautrel B, Gossec L. Patient-physician discordance in global assessment in early spondyloarthritis and its change over time: The DESIR cohort. Ann Rheum Dis. 2016;75(9):1661-1666. doi: 10.1136/annrheumdis-2015-208251

9. Desthieux C, Hermet A, Granger B, Fautrel B, Gossec L. Patientphysician discordance in global assessment in rheumatoid arthritis: A systematic literature review with meta-analysis. Arthritis Care Res (Hoboken). 2016;68(12):1767-1773. doi: 10.1002/acr.22902

10. Guimarães MFBR, Pinto MRDC, Resende GG, Machado CJ, Vargas-Santos AB, Amorim RBC, et al. Discordance between the patient’s and physician’s global assessment in rheumatoid arthritis: Data from the REAL study-Brazil. PLoS One. 2020;15(3):e0230317. doi: 10.1371/journal.pone.0230317

11. Wei W, Sullivan E, Blackburn S, Chen CI, Piercy J, Curtis JR. The prevalence and types of discordance between physician perception and objective data from standardized measures of rheumatoid arthritis disease activity in real-world clinical practice in the US. BMC Rheumatol. 2019;3:25. doi: 10.1186/s41927-019-0073-8

12. Saag KG. OMERACT 6 brings new perspectives to rheumatology measurement research. J Rheumatol. 2003;30(4):639-641.

13. Alves Pereira I, Maldonado Cocco J, Feijó Azevedo V, Guerra G, Bautista-Molano W, Casasola JC, et al. Levels of satisfaction with rheumatoid arthritis treatment and associated alignment between physicians and patients across Latin America. Clin Rheumatol. 2020;39(6):1813-1822. doi: 10.1007/s10067-019-04858-x

14. Furst DE, Tran M, Sullivan E, Pike J, Piercy J, Herrera V, et al. Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control. Clin Rheumatol. 2017;36(9):2045-2054. doi: 10.1007/s10067-017-3578-9

15. De Mits S, Lenaerts J, Vander Cruyssen B, Mielants H, Westhovens R, Durez P, et al.; Be-Raise study group. A nationwide survey on patient’s versus physician’s evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration: The Be-Raise study. PLoS One. 2016;11(11):e0166607. doi: 10.1371/journal.pone.0166607

16. Schäfer M, Albrecht K, Kekow J, Rockwitz K, Liebhaber A, Zink A, et al. Factors associated with treatment satisfaction in patients with rheumatoid arthritis: Data from the biological register RABBIT. RMD Open. 2020;6(3):e001290. doi: 10.1136/rmdopen-2020-001290

17. Fujiwara T, Kondo M, Yamada H, Haraguchi A, Fujimura K, Sakuraba K, et al. Factors affecting patient satisfaction related to cost and treatment effectiveness in rheumatoid arthritis: Results from the multicenter observational cohort study, FRANK Registry. Arthritis Res Ther. 2022;24(1):53. doi: 10.1186/s13075-022-02746-5

18. Alcaide L, Torralba AI, Eusamio Serre J, García Cotarelo C, Loza E, Sivera F. Current state, control, impact and management of rheumatoid arthritis according to patient: AR 2020 national survey. Reumatol Clin (Engl Ed). 2022;18(3):177-183. doi: 10.1016/j.reumae.2021.03.002

19. Tveit KS, Duvetorp A, Østergaard M, Skov L, Danielsen K, Iversen L, et al. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol. 2019;33(2):340-354. doi: 10.1111/jdv.15252

20. Lebwohl MG, Kavanaugh A, Armstrong AW, Van Voorhees AS. US Perspectives in the management of psoriasis and psoriatic arthritis: patient and physician results from the population-based Multinational Assessment of Psoriasis and Psoriatic ARTHRITIS (MAPP) survey. Am J Clin Dermatol. 2016;17(1):87-97. doi: 10.1007/s40257-015-0169-x

21. Kilic L, Erden A, Bingham CO 3rd, Gossec L, Kalyoncu U. The reporting of patient-reported outcomes in studies of patients with rheumatoid arthritis: A systematic review of 250 articles. J Rheumatol. 2016;43(7):1300-1305. doi: 10.3899/jrheum.151177

22. Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – A systematic review and network meta-analysis. Health Qual Life Outcomes. 2014;12:102. doi: 10.1186/1477-7525-12-102

23. Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev. 2016;2016(6):CD008334. doi: 10.1002/14651858.CD008334.pub2

24. Barra L, Ha A, Sun L, Fonseca C, Pope J. Efficacy of biologic agents in improving the Health Assessment Questionnaire (HAQ) score in established and early rheumatoid arthritis: A meta-analysis with indirect comparisons. Clin Exp Rheumatol. 2014;32(3):333-341.

25. Karateev AE, Lila AM, Panevin TS, Potapova AS, Semashko AS, Bobkova AO, et al. Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(4):427-437 (In Russ.). doi: 10.47360/1995-4484-2022-427-437

26. Strand V, Kaine J, Alten R, Wallenstein G, Diehl A, Shi H, et al. Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: A post hoc analysis of data from phase 3 trials of tofacitinib. Arthritis Res Ther. 2020;22(1):243. doi: 10.1186/s13075-020-02324-7

27. Patient’s reported outcomes – a new philosophy for analyzing the effectiveness of therapy in immunoinflammatory diseases. Modern Rheumatology Journal. 2021;15(5):121-127 (In Russ.). doi: 10.14412/1996-7012-2021-5-121-127

28. Keystone E, Movahedi M, Cesta A, Bombardier C, Sampalis JS, Rampakakis E. Differential influence of Clinical Disease Activity Index components based on disease state in rheumatoid arthritis patients: Real-world results from the Ontario Best Practices Research Initiative. Clin Exp Rheumatol. 2022;40(11):2147-2152. doi: 10.55563/clinexprheumatol/86frzq

29. Brkic A, Łosińska K, Pripp AH, Korkosz M, Haugeberg G. Remission or not remission, that’s the question: Shedding light on remission and the impact of objective and subjective measures reflecting disease activity in rheumatoid arthritis. Rheumatol Ther. 2022;9(6):1531-1547. doi: 10.1007/s40744-022-00490-5

30. Duarte C, Ferreira RJO, Santos EJF, da Silva JAP. Treatingto-target in rheumatology: Theory and practice. Best Pract Res Clin Rheumatol. 2022;36(1):101735. doi: 10.1016/j.berh.2021.101735

31. Karateev AE, Pogozheva EYu, Amirdzanova VN, Filatova ES, Nesterenko VA. «I am getting better» and «I feel good»: Searching for an objective criterion for a clinical response to analgesic therapy for rheumatic diseases. Modern Rheumatology Journal. 2020;14(2):90-96 (In Russ.). doi: 10.14412/1996-7012-2020-2-90-96

32. Tubach F, Wells GA, Ravaud P, Dougados M. Minimal clinically important difference, low disease activity state, and patient acceptable symptom state: Methodological issues. J Rheumatol. 2005;32(10):2025-2029.

33. Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, et al. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: The patient acceptable symptom state. Ann Rheum Dis. 2005;64(1):34-37. doi: 10.1136/ard.2004.023028

34. Tubach F, Pham T, Skomsvoll JF, Mikkelsen K, Bjørneboe O, Ravaud P, et al. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis. Arthritis Rheum. 2006;55(6):960-963. doi: 10.1002/art.22342

35. Tubach F, Ravaud P, Beaton D, Boers M, Bombardier C, Felson DT, et al. Minimal clinically important improvement and pa tient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol. 2007;34(5):1188-1193.

36. Puyraimond-Zemmour D, Etcheto A, Fautrel B, Balanescu A, de Wit M, Heiberg T, et al. Associations between five important domains of health and the patient acceptable symptom state in rheumatoid arthritis and psoriatic arthritis: A cross-sectional study of 977 patients. Arthritis Care Res (Hoboken). 2017; 69(10):1504-1509. doi: 10.1002/acr.23176

37. Tubach F, Ravaud P, Martin-Mola E, Awada H, Bellamy N, Bombardier C, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken). 2012;64(11):1699-1707. doi: 10.1002/acr.21747

38. Gwinnutt JM, Hyrich KL, Lunt M; RAMS Co-Investigators, Barton A, Verstappen SMM. Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as ‘satisfactory’. Rheumatology (Oxford). 2020;59(8):1853-1861. doi: 10.1093/rheumatology/kez497

39. Duarte C, Santos E, Kvien TK, Dougados M, de Wit M, Gossec L, et al. Attainment of the patient-acceptable symptom state in 548 patients with rheumatoid arthritis: Influence of demographic factors. Joint Bone Spine. 2021;88(1):105071. doi: 10.1016/j.jbspin.2020.09.003

40. Stocker PH, Jasper MH, Kahlow B, Nisihara R, Skare T. Depression as a major determinant of PASS (Patient’s Acceptable Symptoms State) in rheumatoid arthritis: a cross-sectional study in Brazilian patients. Rev Assoc Med Bras (1992). 2022;68(8):995-999. doi: 10.1590/1806-9282.20220600

41. Heiberg T, Kvien TK, Mowinckel P, Aletaha D, Smolen JS, Hagen KB. Identification of disease activity and health status cutoff points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67(7):967-971. doi: 10.1136/ard.2007.077503

42. Katchamart W, Narongroeknawin P, Suppa-Udom B, Chanapai W, Srisomnuek A. Factors associated with and cutoff points for Patient Acceptable Symptom State (PASS) in rheumatoid arthritis. Clin Rheumatol. 2020;39(3):779-786. doi:10.1007/s10067-019-04860-3

43. Karateev AE, Polishchuk EYu, Potapova AS, Matya nova EV, Semashko AS, Bobkova АO, et al. The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: Data from a telephone survey of 254 patients. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(2):149-156 (In Russ.). doi: 10.47360/1995-4484-2022-149-156

44. Migliore A, Gigliucci G, Alekseeva L, Avasthi S, Bannuru RR, Chevalier X, et al. Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements. Ther Adv Musculoskelet Dis. 2019;11:1759720X19893800. doi: 10.1177/1759720X19893800

45. Uhrenholt L, Høstgaard S, Pedersen JF, Christensen R, Dreyer L, Leffers HCB, et al. Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study. Lupus. 2021;30(13):2124-2134. doi: 10.1177/09612033211051641

46. de Wolff L, Vissink A, van Nimwegen JF, van Zuiden G, Mossel E, Olie L, et al. Patient Acceptable Symptom State (PASS) in patients with primary Sjögren’s syndrome in daily clinical practice. Clin Exp Rheumatol. 2022;40(12):2303-2309. doi: 10.55563/clinexprheumatol/mnqiy9

47. Lorenzin M, Ughi N, Ariani A, Raffeiner B, Frallonardo P, Hoxha A, et al.; SIR Study Group ATTACk. Predictors of disease activity in gout: A 12-month analysis of the ATTACk (Achieving improvement in the management of crystal-induced arthritis) multicentre cohort study. Clin Exp Rheumatol. 2023;41(3):628-633. doi: 10.55563/clinexprheumatol/eh0jcp

48. Daste C, Abdoul H, Foissac F, Lefèvre-Colau MM, Poiraudeau S, Rannou F, et al. Patient acceptable symptom state for patientreported outcomes in people with non-specific chronic low back pain. Ann Phys Rehabil Med. 2022;65(1):101451. doi: 10.1016/j.rehab.2020.10.005

49. Taylor PC. Adopting PROs in virtual and outpatient management of RA. Nat Rev Rheumatol. 2020;16(9):477-478. doi: 10.1038/s41584-020-0449-6

50. Seppen BF, Verkleij SJ, Wiegel J, Ter Wee MM, Nurmohamed MT, Bos WH. Probability of medication intensifications in rheumatoid arthritis patients with low disease activity scores on their patient-reported outcomes: A medical-records review study. J Clin Rheumatol. 2022;28(8):397-401. doi: 10.1097/RHU.0000000000001883

51. Nowell WB, Gavigan K, Kannowski CL, Cai Z, Hunter T, Venkatachalam S, et al. Which patient-reported outcomes do rheumatology patients find important to track digitally? A real-world longitudinal study in ArthritisPower. Arthritis Res Ther. 2021;23(1):53. doi: 10.1186/s13075-021-02430-0

52. Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, et al. Call for action: How to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis. Rheumatol Int. 2018;38(6):935-947. doi: 10.1007/s00296-018-4005-5

53. Uhrenholt L, Christensen R, Dreyer L, Schlemmer A, Hauge EM, Krogh NS, et al. Using a novel smartphone application for capturing of patient-reported outcome measures among patients with inflammatory arthritis: A randomized, crossover, agreement study. Scand J Rheumatol. 2022;51(1):25-33. doi: 10.1080/03009742.2021.1907925

54. Duarte C, Santos E, da Silva JAP, Kristianslund EK, Kvien TK, Dougados M, et al. The Patient Experienced Symptom State (PESS): A patient-reported global outcome measure that may better reflect disease remission status. Rheumatology (Oxford). 2020;59(11):3458-3467. doi: 10.1093/rheumatology/keaa149